Journal de bioéquivalence et de biodisponibilité

Abstrait

Bioavailability and Interaction Potential of Atorvastatin and Losartan on Co-administration in Healthy Human Subjects

Tausif Ahmed, Sivacharan Kollipara, Anirudh Gautam, Radhika Gigras, Monica Kothari, Nilanjan Saha, Vijay Batra and Jyoti Paliwal

A randomized, open-label, balanced, three-treatment, three-sequence, three-period single dose crossover pharma- cokinetic interaction study was conducted to evaluate the potential of interaction between Atorvastatin (AT) and Losartan (LS). Subjects were administered either 40 mg AT or 100 mg LS or combination of both in either of the periods. Blood samples were collected at regular intervals to measure the plasma concentrations of AT, O-hydroxy atorvastatin (O-HAT), LS and its carboxylic acid metabolite (LS-CA) for pharmacokinetic analysis. Co-administration of AT and LS was well tolerated without any significant change in area under the curve (AUC) of either of the drugs or their respective metabolites. There was an increase in C max (ng/mL) of AT, O-HAT, LS, and LS-CA by 29% (38.8(±20.9) to 47.8(±18.4)), 86% (15.7±(10.6) to 29.8(±19.1)), 51% (503.0(±246.0) to 793.0(±376.0)) and 21% (971.0(±245.0) to 1189.0(±323.0)), respectively in combination treatment. Both AT and LS are substrates of P-glycoprotein (P-gp) and CYP3A4, and reported to be completely absorbed from gastrointestinal tract. Hence, this change in the rate of absorption appears to be due to transient saturation of P-gp and/or CYP3A4 during initial absorption phase in the gut wall prior to reaching in portal vein circulation. The increase in C max of both drugs may not be clinically signifi- cant to call for dosage adjustment.